# Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study

> **NCT05652478** · PHASE2 · RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 120 (estimated)

## Conditions studied

- Healthy Volunteer
- Weight Gain
- Metabolic Effects
- Integrase Strand Transfer Inhibitors

## Interventions

- **DRUG:** Dolutegravir (DTG) AND Tenofovir alafenamide (TAF)
- **DRUG:** Tenofovir Disoproxil Fumarate
- **DRUG:** Dolutegravir
- **DRUG:** Tenofovir alafenamide

## Key facts

- **NCT ID:** NCT05652478
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-21
- **Primary completion:** 2028-01-31
- **Final completion:** 2030-01-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05652478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05652478, "Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study". Retrieved via AI Analytics 2026-09-02 from https://api.ai-analytics.org/clinical/NCT05652478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*